Title Page / Contents
S.W.J. Lamberts, David Nott, Kenneth J. O’Byrne(Unknown), Vincenzo Catalano(Azienda Ospedaliero-Universitaria delle Marche), Carmelo Scarpignato(University of Parma), Stefano Cascinu(Marche Polytechnic University), Christiane Susini(Inserm), Iva Pelosini, Anne Thomas(Leicester Royal Infirmary), N. Vaysse, Giuseppina Catalano(Unknown), Andrew V. Schally(Tulane University), Paolo Giordani(University of Genoa), Howard Kynaston(Cardiff University), Corinne Bousquet(Centre National de la Recherche Scientifique), D. Amoroso(Ospedale Versilia), Andrew Dean, Lawrence Rosenberg(McGill University Health Centre), Francesco Boccardo, Iraklis G. Vainas, Kjell Öberg(Moffitt Cancer Center), S A Jenkins, William P. Steward(University of Leicester), Nick Davies, Desmond N. Carney, Anna Maria Baldelli(Azienda Ospedaliero-Universitaria delle Marche), J N Baxter(Penta-Ocean Construction (Japan)), Romina Agostinelli, Elena Puente(Inserm), Elias Kouroumalis(University of Crete)
Cited by 0
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k